NCT06421675
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06421675
Title Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)
Acronym EMBRACE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ontario Clinical Oncology Group (OCOG)
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Vancouver Cancer Center RECRUITING Vancouver British Columbia V5Z 1L3 Canada Details
Juravinski Cancer Center RECRUITING Hamilton Ontario L8V 1C3 Canada Details
London Health Science Centre - Victoria Hospital NOT_YET_RECRUITING London Ontario N6A 5W9 Canada Details
Ottawa Hospital RECRUITING Ottawa Ontario K1H 8L6 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field